Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Iceland Health Focus.
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
GlobeNewswire, Inc.
·
April 16, 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
GlobeNewswire, Inc.
·
March 27, 2025
REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
GlobeNewswire, Inc.
·
April 15, 2025
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
GlobeNewswire, Inc.
·
April 17, 2025
ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet...
Alvogen Completes Comprehensive Refinancing with Longer-Dated Maturity Profile and Reduction of Debt
GlobeNewswire, Inc.
·
March 10, 2025
REYKJAVIK, Iceland and MORRISTOWN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Alvogen Pharma US, Inc. (“Alvogen” or the “Company”), a privately owned US-based pharmaceutical company, has completed a comprehensive refinancing of its capital...
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
GlobeNewswire, Inc.
·
March 20, 2025
REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition...
Oculis Publishes Invitation to the Annual General Meeting
GlobeNewswire, Inc.
·
May 9, 2025
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11,...
Greenland Ice Melt Soars 17x Due to Extreme Heat
MENAFN
·
June 11, 2025
(MENAFN) During an extraordinary May heatwave, Greenland's ice sheet experienced melting at a rate 17 times higher than usual, according to findings released Wednesday by the World Weather Attribution (WWA) network. “Temperatures over Iceland as...
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
GlobeNewswire, Inc.
·
April 1, 2025
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire, Inc.
·
March 20, 2025
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG)...
Landmark Study Identifies New Genetic Cause of Neurodevelopmental Disorders, Bringing Long-Awaited Answers to Families
GlobeNewswire, Inc.
·
April 10, 2025
New York, NY, April 10, 2025 (GLOBE NEWSWIRE) -- A seminal study from researchers at the Icahn School of Medicine at Mount Sinai and their collaborators in the United Kingdom, Belgium, Spain, the Netherlands, and Iceland has uncovered a new...
IceNetworks Ltd./www.mega-pillspharmacy.com - 610218 - 08/31/2020
U.S. Food and Drug Administration
·
March 19, 2025
Recipient: IceNetworks Ltd./www.mega-pillspharmacy.com Iceland Issuing Office: Center for Drug Evaluation and Research | CDER United States DATE: August 31, 2020 WARNING LETTER The United States (U.S.) Food and Drug Administration (FDA) has...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire, Inc.
·
February 28, 2025
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswire, Inc.
·
February 18, 2025
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals,...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswire, Inc.
·
February 18, 2025
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals,...
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
GlobeNewswire, Inc.
·
March 18, 2025
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech...
US Antimicrobial Plastics Market Set to Expand at a 8.20% CAGR, Reaching USD 14.634 Billion by 2032
EIN Presswire
·
April 29, 2025
The US Antimicrobial Plastics market segmentation, based on additive includes Inorganic (Silver, Zinc, Copper) and Organic (ОВРА, Triclosan). NEW YORK, NJ, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- The US Antimicrobial Plastics Market...
UPDATE – The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
GlobeNewswire, Inc.
·
April 30, 2025
STUDIO CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime philanthropist John O’Dwyer, who lived with myeloma...
The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
GlobeNewswire, Inc.
·
April 29, 2025
STUDIO CITY, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime philanthropist John O’Dwyer, who lived with myeloma...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
GlobeNewswire, Inc.
·
January 27, 2025
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals,...